| Autor: |
Bisceglia, Luisa, Morani, Federica, Guerrieri, Lara, Santoni-Rugiu, Eric, Çakılkaya, Pınar, Scatena, Cristian, Scarpitta, Rosa, Engelholm, Lars H., Behrendt, Niels, Gemignani, Federica, Landi, Stefano |
| Zdroj: |
Cancer Gene Therapy; 20240101, Issue: Preprints p1-13, 13p |
| Abstrakt: |
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis and the identification of novel druggable targets is urgently needed. In previous work, we identified 15 deregulated genes highly expressed in MPM tissues and correlated with a poor prognosis. Here, we validated these findings on an independent dataset of 211 MPM patients (EGA, EGAD00001001915) and on a panel of MPM cell lines. Furthermore, we carried out in vitro gene silencing followed by proliferation, cytotoxicity, caspase, and migration assays to define whether these targets could be cancer-driver genes. We ended up with three novel candidates (i.e., BAG2, MAD2L1, and MDK), whose encoded proteins could be exploited as druggable targets. Moreover, of novelty, immunohistochemistry analysis on tissues revealed that the overexpression of BAG2 and MAD2L1 could differentiate MPM from RMP patients. Furthermore, when we tested Neratinib (an inhibitor of MAD2L1) and iMDK (an inhibitor of MDK) we found that they are effective on MPM cells, in part phenocopying the effects of MAD2L1and MDKgene silencing. In summary, in the present work, we report that BAG2, MAD2L1, and MDKare bona fide cancer-driver genes for MPM worth of further studies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink